Breast and ovarian cancer are the most common malignant tumors in women. They have a long latency period and no obvious early onset symptoms, but a high mortality rate. At present, 14 different types of tumors account for about 80% of all cancers, among which breast cancer and ovarian cancer often top the list because of their dangerous degree.Studies have shown that more than 220,000 women worldwide suffer from ovarian cancer, and about 60% of them die every year. In China, on average, there is one woman having breast cancer every 3 minutes and one woman dying of breast cancer every 10 minutes.
Bispecific antibodies (BsAb) are also called bifunctional antibodies, which are constructed by gene recombination, chemical coupling or quadruple hybridoma, and can specifically bind to two antigens or two epitope antibody molecules at the same time. Compared with common antibodies, BsAb have stronger specificity, obvious advantages in killing tumor cells by T cells, off-target toxicity, clinical indications, etc., as well as functions that a single target antibody can't achieve.
Bispecific antibody (BsAb) has been proved to be an effective targeting vector for targeted radioimmunotherapy (PRIT).
In a human-derived xenograft model of breast/ovarian cancer (HER2/HER3), we are conducting a series of preclinical studies (212pb-BSA-U071, 227Th-BsAb-U071) on α-PRIT therapy.
Human epidermal growth factor receptor type 2 (HER2) is a well-recognized tumor target that is over-expressed in a variety of cancers, including breast, ovarian, lung, gastric, and oral cancers. It has been proved to be a molecular target of therapeutic intervention, a prognostic indicator of patient survival, and a predictive marker of anti-tumor therapeutic response. Many radionuclides including 18F, 99mTc, 111In, 90Y, 177Lu, 68Ga, 125I, 76/77/82Br, and 211At have been used to label anti-HER2 antibody molecules for tumor imaging or radiotherapy. These studies have clearly demonstrated that antibody molecules are a promising new class of cancer targeting ligands.
We are developing a 64Cu-labeled anti-HER2 antibody targeting human epidermal growth factor receptor 2(HER2) to rapidly and noninvasively assess the expression status of HER2.